Occurrence of Hepatocellular Carcinoma Was Not a Rare Event during and Immediately after Antiviral Treatment in Japanese HCV-Positive Patients
Occurrence of Hepatocellular Carcinoma Was Not a Rare Event during and Immediately after Antiviral Treatment in Japanese HCV-Positive Patients
复制标题
DOI：
10.1159/000330549
复制
发表时间：
2011-01-01
期刊：
影响因子：
3.5
通讯作者：
Yokosuka, Osamu
中科院分区：
文献类型：
--
作者：
Kanda, Tatsuo;Imazeki, Fumio;Yokosuka, Osamu
抗病毒药物持续病毒学应答的晚期慢性丙型肝炎患者仍有患肝细胞癌的风险。我们调查了日本慢性丙型肝炎患者在聚乙二醇干扰素-α-2a和利巴韦林(RBV)治疗期间和治疗后立即发生肝细胞癌的情况。238例患者中有8例在治疗期间和治疗后发现了肝细胞癌(平均随访期：5728252天)。总之，在聚乙二醇干扰素-α-2a联合RBV治疗期间和治疗后立即发生肝细胞癌并不少见。对于有肝硬变、甲胎蛋白水平较高、年龄较大或既往有肝细胞癌治疗史的患者，临床医生应特别警惕在聚乙二醇α-2a和RBV治疗期间和之后可能发生的肝细胞癌。临床医生应该定期检查肝癌的可能发展，即使是正在接受治疗的慢性丙型肝炎患者也是如此。版权所有(C)2011 S.Karger AG，巴塞尔
Advanced chronic hepatitis C patients with sustained virolological response by antivirals remain at risk for hepatocellular carcinoma (HCC). We investigated the incidence of HCC during and immediately after peginterferon-alfa-2a and ribavirin (RBV) treatment in patients with chronic hepatitis C in Japan. HCC was detected in 8 of 238 patients during and after these treatments (mean follow-up period: 572 8 252 days). In conclusion, occurrence of HCC is not a rare event during and immediately after peginterferon-alfa-2a plus RBV treatment. In cases with cirrhosis, higher alpha-fetoprotein levels, old age, or a previous history of HCC treatment, clinicians should be especially alert for the possible development of HCC during and immediately after peginterferon-alfa-2a and RBV treatment. Clinicians should regularly check for the possible development of HCC even in chronic hepatitis C patients under treatment. Copyright (C) 2011 S. Karger AG, Basel